<DOC>
	<DOC>NCT01738282</DOC>
	<brief_summary>The purpose of the study is to assess the efficacy of Xylka® (baclofen) compared to placebo on continuous abstinence rate during 20 weeks of treatment, after withdrawal, in alcohol dependent patients receiving Brenda therapy sessions.</brief_summary>
	<brief_title>Efficacy and Safety of Baclofen for Maintenance of Abstinence in Alcohol Dependent Patients</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>Adult patients meeting DSM IV(Diagnosis and Statistical Manual of Mental Disorders, 4th edition) criteria for alcohol dependence Willing to participate in the study and express a desire to achieve the objective of continuous and long term abstinence after withdrawal Abstinent (last drinking) for a minimum of 3 days and maximum of 14 days At least one previous abstinence attempt Need for a stay at the end of the withdrawal period in a health care and rehabilitation institution specialized in addiction Need for a heavy psychosocial out of hospital care History of baclofen intake, by prescription or self medication Porphyria Concomitant treatment with one or several drugs for the maintenance of abstinence Severe renal, cardiac or pulmonary disorder Epilepsy or history of epilepsy Concomitant treatment with psychotropic drugs, except antidepressants at stable dose for 2 months, diazepam and oxazepam Severe psychiatric disease (schizophrenia and bipolar disorder) Suicidal risk or history of suicide Clinically significant cognitive disorders Hepatic encephalopathy Ongoing dependence or within the last 12 months on other addictive substances (opioid, cocaine, cannabis, other substances or drugs…), excepted tobacco</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>baclofene</keyword>
	<keyword>Alcohol dependence</keyword>
	<keyword>Maintenance of abstinence</keyword>
</DOC>